A recent study in JAMA Dermatology evaluated drug survival rates in pediatric atopic dermatitis, finding that dupilumab demonstrated the highest 1-year survival rate of 84.1% among patients. The study offers valuable insights into the long-term effectiveness and safety of systemic therapies in pediatric patients with atopic dermatitis.
New study: Maternal COVID-19 exposure in utero not linked to increased risk of neurodevelopmental delays in children through 24 months. Read more in JAMA Network Open.
A recent study found that women who exercised three or more times per week during pregnancy decreased the risk of their children developing asthma, aligning with current guidelines for physical activity during pregnancy.
A study of over 36,000 patients revealed 25% of asthma patients and 21.6% of COPD patients switched from dry powder inhalers to pressurized metered-dose inhalers in the previous year, highlighting significant device changes in real-world practice.
Discover the concerning racial bias in pulse oximeters' readings, impacting patient care and outcomes, and the ongoing efforts to address this critical issue. #Healthcare #RacialBias
KFF Health News
Daily News
Stay up to date with the latest clinical headlines.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
In a phase 3 trial, 67% of children treated with omalizumab tolerated 600 mg of peanut protein, a dramatic increase over just 7% with placebo, highlighting omalizumab’s potential in managing pediatric food allergies.
New research compares human milk antibody levels against infectious pathogens across different income countries, revealing important insights for infant health.
Two phase III clinical trials reveal promising results of once-daily roflumilast cream, 0.15%, in improving symptoms of atopic dermatitis within 4 weeks.